Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Paraproteinemias 1Lymphoproliferative Disorders 1Hemostatic Disorders 1Hematologic Diseases 1

Interventions

zanubrutinib 9ibrutinib 9Rituximab 5idelalisib 4venetoclax 3pirtobrutinib 3ublituximab 2bazlitoran 2acalabrutinib 2Dexamethasone 2ARQ531 2umbralisib 1selinexor 1sapanisertib 1pomalidomide 1perifosine 1pembrolizumab 1ontuxizumab 1ofatumumab 1obinutuzumab 1mavorixafor 1loncastuximab tesirine 1fludarabine 1epratuzumab 1enzastaurin 1carfilzomib 1brexucabtagene autoleucel 1WW Domain-Containing Oxidoreductase 1Voriconazole 1Vitamin B 12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Waldenstrom Macroglobulinemia × epratuzumab × Clear all
NCT00113802 2021-08-19

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Gilead Sciences

Phase 2 Terminated
31 enrolled
Lymphoid

Hematologic Diseases, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Paraproteinemias, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡